Why study Nivolumab?

Nivolumab is an investigational compound being studied as a potential treatment option for lung cancer, renal cell carcinoma (kidney cancer), and melanoma.11/15/2013
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news

Related Links:

CONCLUSIONS: Human tumor data suggest that NSCLC, RCC, and melanoma should be the tumor subtypes prioritized for anti-GITR therapy development. PMID: 31358539 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Interview with Suzanne L. Topalian, author of Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
Source: JAMA Specialty Journals Author Interviews - Category: General Medicine Source Type: podcasts
(Johns Hopkins Medicine) A research team led by experts at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center reports favorable five-year survival rates from the first multidose clinical trial of the immunotherapy drug nivolumab (anti-PD-1) as a treatment for patients whose previous therapies failed to stem their advanced melanoma, renal cell carcinoma (RCC) or non-small-cell lung cancer (NSCLC).
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Publication date: Available online 11 July 2019Source: American Journal of Kidney DiseasesAuthor(s): Roman Shingarev, Ilya G. GlezermanImmunologic control of malignancy has long been recognized as an important determinant of disease progression. Recent advances in immunology have led to the focus on several mechanisms that can be targeted to achieve tumor suppression. In particular, checkpoint inhibition has evolved in less than a decade to become one of the most important strategies in cancer therapy, with a meaningful improvement in patient survival. Six agents have been approved for clinical use to date and many more ar...
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
CONCLUSION: This large, multivariate analysis demonstrated that antibiotic use is an independent negative predictor of PFS and OS in patients with advanced cancer treated with ICIs. This study highlighted worse treatment outcomes from patients with cumulative (multiple or prolonged courses) antibiotic use, which warrants further investigation and may subsequently inform clinical practice guidelines advocating careful use of antibiotics. IMPLICATIONS FOR PRACTICE: Antibiotic use is negatively associated with treatment outcomes of immune checkpoint inhibitors (ICI) in advanced cancer. Cumulative antibiotic use is associ...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
This review focuses on what is the biological basis of esophageal cancer for immunotherapy, how to screen out the patients who can benefit from immunotherapy, and whether the toxic side effects of immunotherapy are manageable. AbstractConsidering the benefits of immunotherapy in advanced melanoma, non –small cell lung cancer, renal cell carcinoma, bladder cancers, and refractory Hodgkin lymphoma, we begin to consider whether immunotherapy is effective for esophageal cancer, which is extremely malignant and has a poor prognosis. There are a large number of clinical trials to study the applicatio n of immunotherapy suc...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: REVIEW Source Type: research
Surveillance imaging in patients with a history of solid organ malignancies has led to increased identification of asymptomatic adrenal masses, which raises clinical ambiguity in patients with known prior or concurrent malignancies. Single adrenal masses (incidentalomas) are found incidentally in 2%-9% of all abdominal CT scans. Adrenal metastases are most commonly seen in renal cell carcinoma, melanoma, lung cancer, colon cancer and lymphoma. The involvement of adrenal gland upstages the disease.
Source: Gastrointestinal Endoscopy - Category: Gastroenterology Authors: Tags: Tuesday abstract Source Type: research
Lung cancer remains the leading cause of cancer deaths worldwide[1]. Non-small cell lung cancer (NSCLC) represents 80-90% of lung primary malignancies. NSCLC is most often diagnosed at a metastatic stage, where 5-year survival rate ranges between 0 and 5% using traditional chemotherapy-based strategies[2]. The recent introduction of immune checkpoint inhibitors (ICI), has resulted in an increase in overall survival (OS) rates of patients with advanced NSCLC, as well as melanoma, urothelial carcinoma, renal cell carcinoma and head and neck carcinoma.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Conclusions: To develop small molecule-based PD-L1 PET imaging probes, we designed and synthesized a library of fluorinated PD-L1 ligands based on the biphenyl pharmacophore. In vitro binding assay showed that several of the compounds possess nano-molar affinities to human PD-L1, and are potential PD-L1 PET imaging probe candidates. The radiolabeling and in vitro and in vivo pharmacology and pharmacokinetics studies of these PET tracers are under the way. Figure 1. The structure of the lead compound and the regions for SAR
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Novel Radiochemistry for Cancer Applications Source Type: research
AbstractCancer cells can escape the immune system by different mechanisms. The evasion of cancer cells from immune surveillance is prevented by immune checkpoint inhibitors, allowing the patient ’s own immune system to attack their cancer. Immune checkpoint inhibitors have shown improvement in overall survival for melanoma, lung cancer and renal cell carcinoma in clinical trials. Unfortunately, not all patients respond to this therapy.In cancer management, percutaneous ablation techniques are well established for both cure and local control of many tumour types. Cryoablation of the tumour tissue results in cell destr...
Source: Insights into Imaging - Category: Radiology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Lung Cancer | Melanoma | Renal Cell Carcinoma | Skin Cancer | Study | Urology & Nephrology